



*Collaboration. Acceleration. Results.*

## **The Myelin Repair Foundation Partners with Genzia Corporation to Advance Myelin Repair Therapeutics for Multiple Sclerosis (MS)**

**SARATOGA, CA and CHARLOTTESVILLE, VA— August 13, 2013**—The [Myelin Repair Foundation](#) (MRF) and Genzia Corporation today announced a collaboration to advance myelin repair therapeutic development for Multiple Sclerosis (MS). Through its unique [Accelerated Research Collaboration™ \(ARC™\) model](#), the Myelin Repair Foundation will partner with Genzia Corporation to assess the myelin regenerating capabilities of the company's proprietary therapeutic compounds for MS.

Through this unique partnership, Genzia Corporation will work closely with researchers at the Myelin Repair Foundation's Translational Medicine Center, a laboratory facility dedicated to the evaluation of promising multiple sclerosis candidates for myelin repair. Led by MRF personnel with extensive biopharma experience moving therapeutic compounds into the clinic, the MRF Translational Medicine Center investigates and advances promising myelin repair drug targets toward commercialization.

"The Myelin Repair Foundation's patient-centric, collaborative approach to develop the next generation of MS therapeutics makes them an ideal partner for us to bring new treatments to the clinic," said President and CEO Allen Cunningham from Genzia Corporation. "We are excited to work side by side with MRF, utilizing their novel myelin repair research tools and assays at the MRF Translational Medicine Center. With this partnership, we are well positioned to expedite myelin repair therapeutics development forward, meeting the needs of MS patients."

"Genzia's forward-thinking approach to remyelination aligns nicely with our goal to bring the next generation of MS treatments to patients," said [Chief Research Officer Dr. Jay Tung, Ph.D.](#), from the Myelin Repair Foundation. "We are thrilled to be working with Genzia to examine new ways to treat MS. As a non-profit organization, we seek to partner with innovative companies doing exciting MS research in myelin repair."

The Myelin Repair Foundation's rigorous, industry-leading [Translational Medicine Platform](#) consists of its Translational Medicine Center, contract research organizations and the [MRF's research consortium](#). The goal of the MRF Translational Medicine Platform is to ensure comprehensive validation of potential therapeutics into clinical development.

### **About the Myelin Repair Foundation**

The Myelin Repair Foundation (MRF) ([www.myelinrepair.org](http://www.myelinrepair.org)) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for Multiple Sclerosis. Its [Accelerated Research Collaboration™ \(ARC™\) model](#) is designed to optimize the process of medical research, drug development and the delivery of new patient treatments.

## **About GENCIA, Corporation**

Gencia Corporation is a privately held biopharmaceutical company focused on discovering and developing novel therapeutics to treat disease. The company's programs leverage the fundamental role that mitochondria play in health, aging and disease. Gencia's pipeline contains biologics and small molecules for the treatment of central nervous system (CNS) disease, inflammation and rare genetic disorders.

### **Contact for Media Inquiries:**

Jennifer Chang

Director of Communications

The Myelin Repair Foundation

[jchang@myelinrepair.org](mailto:jchang@myelinrepair.org)

408-871-2410